JP2003504018A - 核酸合成の感度および特異性の増大のための組成物および方法 - Google Patents
核酸合成の感度および特異性の増大のための組成物および方法Info
- Publication number
- JP2003504018A JP2003504018A JP2001508332A JP2001508332A JP2003504018A JP 2003504018 A JP2003504018 A JP 2003504018A JP 2001508332 A JP2001508332 A JP 2001508332A JP 2001508332 A JP2001508332 A JP 2001508332A JP 2003504018 A JP2003504018 A JP 2003504018A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polymerase
- oligonucleotide
- inhibitor
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 136
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000001668 nucleic acid synthesis Methods 0.000 title claims abstract description 41
- 230000001965 increasing effect Effects 0.000 title description 7
- 230000035945 sensitivity Effects 0.000 title description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 333
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 318
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 318
- 239000003112 inhibitor Substances 0.000 claims abstract description 170
- 230000000694 effects Effects 0.000 claims abstract description 153
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 91
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 69
- 230000003321 amplification Effects 0.000 claims abstract description 66
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 47
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 36
- 238000012163 sequencing technique Methods 0.000 claims abstract description 30
- 108091034117 Oligonucleotide Proteins 0.000 claims description 126
- 102100034343 Integrase Human genes 0.000 claims description 115
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 106
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 75
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 75
- 239000002773 nucleotide Substances 0.000 claims description 72
- 125000003729 nucleotide group Chemical group 0.000 claims description 72
- 108020004414 DNA Proteins 0.000 claims description 64
- 102000053602 DNA Human genes 0.000 claims description 64
- 102000004190 Enzymes Human genes 0.000 claims description 61
- 108090000790 Enzymes Proteins 0.000 claims description 61
- 230000005764 inhibitory process Effects 0.000 claims description 42
- 241000700605 Viruses Species 0.000 claims description 35
- 230000000295 complement effect Effects 0.000 claims description 34
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 32
- 230000004048 modification Effects 0.000 claims description 24
- 238000012986 modification Methods 0.000 claims description 24
- 239000002299 complementary DNA Substances 0.000 claims description 23
- 108020004999 messenger RNA Proteins 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 19
- 108091028664 Ribonucleotide Proteins 0.000 claims description 16
- 108010006785 Taq Polymerase Proteins 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 16
- 239000002336 ribonucleotide Substances 0.000 claims description 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 101710163270 Nuclease Proteins 0.000 claims description 9
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 9
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 101710203526 Integrase Proteins 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 70
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 13
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 82
- 108090000623 proteins and genes Proteins 0.000 description 55
- 229920002477 rna polymer Polymers 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 29
- 238000010804 cDNA synthesis Methods 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 108020004635 Complementary DNA Proteins 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 15
- 238000006116 polymerization reaction Methods 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 108060002716 Exonuclease Proteins 0.000 description 10
- 239000002981 blocking agent Substances 0.000 description 10
- 102000013165 exonuclease Human genes 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 108010010677 Phosphodiesterase I Proteins 0.000 description 9
- 239000005546 dideoxynucleotide Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108010068698 spleen exonuclease Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000001226 triphosphate Substances 0.000 description 9
- 235000011178 triphosphate Nutrition 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000000536 complexating effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000013599 cloning vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000337 buffer salt Substances 0.000 description 4
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- -1 aqueous based Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000005549 deoxyribonucleoside Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 102220240796 rs553605556 Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 101150025719 Nf2 gene Proteins 0.000 description 2
- 241000205160 Pyrococcus Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000204652 Thermotoga Species 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 2
- ZXZIQGYRHQJWSY-NKWVEPMBSA-N [hydroxy-[[(2s,5r)-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 ZXZIQGYRHQJWSY-NKWVEPMBSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical group CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PSOZMUMWCXLRKX-UHFFFAOYSA-N 2,4-dinitro-6-pentan-2-ylphenol Chemical compound CCCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O PSOZMUMWCXLRKX-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 101900144306 Cauliflower mosaic virus Reverse transcriptase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241001383213 Idiodonus aurantiacus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000018427 Iphisa elegans Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 241000202974 Methanobacterium Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100172630 Mus musculus Eri1 gene Proteins 0.000 description 1
- 241001429274 Mycobacterium virus L5 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000192581 Synechocystis sp. Species 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 241000204673 Thermoplasma acidophilum Species 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
- AZJLCKAEZFNJDI-DJLDLDEBSA-N [[(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 AZJLCKAEZFNJDI-DJLDLDEBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 108010068991 arginyl-threonyl-prolyl-prolyl-prolyl-seryl-glycine Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- YXAZULPIBAGTKR-UHFFFAOYSA-N rev antisense Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(S)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)CO)C(O)C1 YXAZULPIBAGTKR-UHFFFAOYSA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14207299P | 1999-07-02 | 1999-07-02 | |
| US60/142,072 | 1999-07-02 | ||
| PCT/US2000/018256 WO2001002559A1 (en) | 1999-07-02 | 2000-06-30 | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010232252A Division JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504018A true JP2003504018A (ja) | 2003-02-04 |
| JP2003504018A5 JP2003504018A5 (enExample) | 2007-10-25 |
Family
ID=22498453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508332A Pending JP2003504018A (ja) | 1999-07-02 | 2000-06-30 | 核酸合成の感度および特異性の増大のための組成物および方法 |
| JP2010232252A Pending JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010232252A Pending JP2011041572A (ja) | 1999-07-02 | 2010-10-15 | 核酸合成の感度および特異性の増大のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1196559B1 (enExample) |
| JP (2) | JP2003504018A (enExample) |
| AT (1) | ATE332371T1 (enExample) |
| AU (1) | AU782555B2 (enExample) |
| CA (1) | CA2377780A1 (enExample) |
| DE (1) | DE60029225T2 (enExample) |
| NZ (1) | NZ516894A (enExample) |
| WO (1) | WO2001002559A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008516613A (ja) * | 2004-10-18 | 2008-05-22 | ブランデイズ ユニバーシティー | Ｐｃｒ増幅での再現性の改善およびミスプライミングの低減のための試薬および方法 |
| JP2009509565A (ja) * | 2005-10-03 | 2009-03-12 | アプレラ コーポレイション | 核酸を増幅するための組成物、方法およびキット |
| WO2013162026A1 (ja) * | 2012-04-27 | 2013-10-31 | 株式会社カネカ | 核酸の増幅方法、および、増幅核酸の検出方法 |
| JP2015512651A (ja) * | 2012-04-12 | 2015-04-30 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 重合反応のための合成核酸 |
| WO2015076356A1 (ja) * | 2013-11-22 | 2015-05-28 | 株式会社カネカ | 短鎖ｒｎａの検出方法 |
| US9920356B2 (en) | 2010-11-24 | 2018-03-20 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
| JP2023505398A (ja) * | 2019-12-11 | 2023-02-08 | ジェノテック コーポレイション | 対立遺伝子の区分性を高めるｐｃｒ方法及びｐｃｒキット |
| JP2023531027A (ja) * | 2020-06-22 | 2023-07-20 | ▲蘇▼州新海生物科技股▲ふん▼有限公司 | 核酸リガンド、およびその使用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3681729B2 (ja) | 2001-02-15 | 2005-08-10 | タカラバイオ株式会社 | 塩基置換の検出方法 |
| CA2498777C (en) * | 2002-09-13 | 2015-01-13 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| WO2007038422A2 (en) | 2005-09-26 | 2007-04-05 | Allelogic Biosciences Corp. | Oligonucleotides as temperature-sensitive inhibitors for dna polymerases |
| US7781165B2 (en) | 2005-10-19 | 2010-08-24 | Roche Diagnostics Operations, Inc. | Benzimidazolium compounds and salts of benzimidazolium compounds for nucleic acid amplification |
| ES2955993T3 (es) * | 2018-01-05 | 2023-12-11 | Hoffmann La Roche | Mejora de la polimerización de los ácidos nucleicos mediante compuestos aromáticos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997041141A1 (en) * | 1996-05-01 | 1997-11-06 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
| JPH11507223A (ja) * | 1995-06-07 | 1999-06-29 | ネクスター ファーマスーティカルズ，インコーポレイテッド | Ｄｎａポリメラーゼに対する結合・阻害核酸リガンド |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
-
2000
- 2000-06-30 EP EP00943373A patent/EP1196559B1/en not_active Expired - Lifetime
- 2000-06-30 NZ NZ516894A patent/NZ516894A/en unknown
- 2000-06-30 DE DE60029225T patent/DE60029225T2/de not_active Expired - Lifetime
- 2000-06-30 CA CA002377780A patent/CA2377780A1/en not_active Abandoned
- 2000-06-30 JP JP2001508332A patent/JP2003504018A/ja active Pending
- 2000-06-30 AU AU57850/00A patent/AU782555B2/en not_active Ceased
- 2000-06-30 WO PCT/US2000/018256 patent/WO2001002559A1/en not_active Ceased
- 2000-06-30 AT AT00943373T patent/ATE332371T1/de not_active IP Right Cessation
-
2010
- 2010-10-15 JP JP2010232252A patent/JP2011041572A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507223A (ja) * | 1995-06-07 | 1999-06-29 | ネクスター ファーマスーティカルズ，インコーポレイテッド | Ｄｎａポリメラーゼに対する結合・阻害核酸リガンド |
| WO1997041141A1 (en) * | 1996-05-01 | 1997-11-06 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008516613A (ja) * | 2004-10-18 | 2008-05-22 | ブランデイズ ユニバーシティー | Ｐｃｒ増幅での再現性の改善およびミスプライミングの低減のための試薬および方法 |
| JP2013063070A (ja) * | 2004-10-18 | 2013-04-11 | Brandeis Univ | Ｐｃｒ増幅での再現性の改善およびミスプライミングの低減のための試薬および方法 |
| JP2009509565A (ja) * | 2005-10-03 | 2009-03-12 | アプレラ コーポレイション | 核酸を増幅するための組成物、方法およびキット |
| US10829805B2 (en) | 2010-11-24 | 2020-11-10 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
| US9920356B2 (en) | 2010-11-24 | 2018-03-20 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
| JP2015512651A (ja) * | 2012-04-12 | 2015-04-30 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 重合反応のための合成核酸 |
| JP2018019699A (ja) * | 2012-04-12 | 2018-02-08 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 重合反応のための合成核酸 |
| US9783844B2 (en) | 2012-04-27 | 2017-10-10 | Kaneka Corporation | Method for amplifying nucleic acid and method for detecting amplified nucleic acid |
| JPWO2013162026A1 (ja) * | 2012-04-27 | 2015-12-24 | 株式会社カネカ | 核酸の増幅方法、および、増幅核酸の検出方法 |
| JP2018038406A (ja) * | 2012-04-27 | 2018-03-15 | 株式会社カネカ | 核酸の増幅方法、および、増幅核酸の検出方法 |
| WO2013162026A1 (ja) * | 2012-04-27 | 2013-10-31 | 株式会社カネカ | 核酸の増幅方法、および、増幅核酸の検出方法 |
| JPWO2015076356A1 (ja) * | 2013-11-22 | 2017-03-16 | 株式会社カネカ | 短鎖ｒｎａの検出方法 |
| WO2015076356A1 (ja) * | 2013-11-22 | 2015-05-28 | 株式会社カネカ | 短鎖ｒｎａの検出方法 |
| US10392652B2 (en) | 2013-11-22 | 2019-08-27 | Kaneka Corporation | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end |
| JP2023505398A (ja) * | 2019-12-11 | 2023-02-08 | ジェノテック コーポレイション | 対立遺伝子の区分性を高めるｐｃｒ方法及びｐｃｒキット |
| JP7541586B2 (ja) | 2019-12-11 | 2024-08-28 | ジェノテック コーポレイション | 対立遺伝子の区分性を高めるｐｃｒ方法及びｐｃｒキット |
| JP2023531027A (ja) * | 2020-06-22 | 2023-07-20 | ▲蘇▼州新海生物科技股▲ふん▼有限公司 | 核酸リガンド、およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2377780A1 (en) | 2001-01-11 |
| AU782555B2 (en) | 2005-08-11 |
| NZ516894A (en) | 2004-06-25 |
| EP1196559A1 (en) | 2002-04-17 |
| WO2001002559A9 (en) | 2002-07-25 |
| WO2001002559A1 (en) | 2001-01-11 |
| DE60029225T2 (de) | 2007-07-05 |
| DE60029225D1 (de) | 2006-08-17 |
| AU5785000A (en) | 2001-01-22 |
| JP2011041572A (ja) | 2011-03-03 |
| EP1196559B1 (en) | 2006-07-05 |
| ATE332371T1 (de) | 2006-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8043816B2 (en) | Compositions and methods for temperature-dependent nucleic acid synthesis | |
| JP2011041572A (ja) | 核酸合成の感度および特異性の増大のための組成物および方法 | |
| JP4289443B2 (ja) | Ｐｃｒの過程でｄｎａ断片の増幅を抑制する方法 | |
| EP0962526B1 (en) | Method for reversible modification of thermostable enzymes | |
| US5739311A (en) | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases | |
| US5681726A (en) | Method of double stranded DNA synthesis | |
| JP2003535587A (ja) | 低温感受性変異体ｄｎａポリメラーゼ | |
| JPWO2000056877A1 (ja) | 核酸配列の増幅方法 | |
| EP2756098A2 (en) | Nucleic acid transcription method | |
| JPH10510161A (ja) | 末端反復増幅方法 | |
| EA035092B1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
| EP1132470B1 (en) | METHOD FOR SYNTHESIZING cDNA | |
| JPWO2004040019A1 (ja) | 核酸の増幅法 | |
| JP4284063B2 (ja) | 核酸塩基配列決定方法 | |
| WO1996040901A1 (en) | Template and primer based synthesis of enzymatically cleavable oligonucleotides | |
| JP5216203B2 (ja) | プルーフリーディング特性を有するｄｎａポリメラーゼを用いるポリメラーゼ連鎖反応のための方法 | |
| US5652126A (en) | Use of restriction endonuclease sequences for cleaving phosphorothioate oligonucleotides | |
| JP4104285B2 (ja) | Ｄｎａ増幅方法及びそのキット | |
| JPWO1999009213A1 (ja) | Ｄｎａ増幅方法及びそのキット | |
| US20060204973A1 (en) | Methods for synthesizing polynucleotides using a single primer | |
| JP2006271250A (ja) | 塩基配列決定方法 | |
| JP2005013122A (ja) | 遺伝子増幅試薬の安定化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070629 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070702 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070702 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100415 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100713 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100721 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101215 |